• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
162682 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  8 W- I# _0 \# h; |# X

: n0 w. b- ^7 ]8 X2 w
3 s$ W, ?$ _1 P1 Y+ h, {Sub-category:5 _/ }1 M( I' x- z: k6 d8 ~
Molecular Targets , ]. t6 _4 b3 \! v- M6 t
" |# A2 j" p& A
0 ?/ x: z' ~3 U! H( ]
Category:
0 k7 a7 P" J: K; _9 J4 R" v( ^* mTumor Biology
' o0 B% S' H# g, A$ A
3 B4 y5 ~8 P/ I! i
* ~* d3 B1 A7 a; X" L9 ~Meeting:4 i5 \5 `  j1 [6 N0 P; ?
2011 ASCO Annual Meeting
( Z+ s) n* U8 |; z9 r/ [5 _  L' u
4 J3 p5 p+ x1 q/ K
. {# O' p* C" ^% QSession Type and Session Title:
; a6 Q4 |! _3 _Poster Discussion Session, Tumor Biology
+ c% Z" ~3 ]5 D
4 ]8 u: j) g# o( ~9 ~; W$ a
8 x+ G3 ]7 U5 X, f, F( n$ EAbstract No:
" G6 G: P  d+ `' \3 {+ G0 h10517 , U% R4 Z. F. Z  r+ }" D1 v

# Z- }' ~' U. v
" |) J' ^$ m0 [! I: r" WCitation:
- E! ?* K4 y' B3 f! T& O7 @( Q# TJ Clin Oncol 29: 2011 (suppl; abstr 10517)
2 ^8 n; S/ Y( B2 W8 M: p
. h9 }! i( S! J8 s( Q1 T. [% n4 V% @& A6 |4 ^% E
Author(s):: ]# @: y2 L6 z1 W2 h- e5 W, Y: ?
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China & |( x. j5 p  X0 ^

# c$ y+ R) s+ x" u
8 i3 V$ T4 ^7 n$ u, ^
+ k8 w" w8 N; ~; d5 U- d" f% Y: TAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.- b2 o9 [: z- @5 c7 [

9 W  f- Z1 N! R8 S  y2 }, v: hAbstract Disclosures7 i4 Y1 k& Y' |( s+ c. U& i0 t

! _2 V5 Q2 i7 FAbstract:5 q" ~0 p  \2 }  K* q  v. M7 p

: f  t8 N/ R. M( I5 M
  X, {0 @( p% I: C& j$ aBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.3 P. s2 E  f$ t+ @+ G9 a* b! V9 u  b
  c0 E, o( Z& Z  A5 d, r

  O0 i5 {5 a; Q( d, M
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
6 X4 R$ t! |" g/ H# Z$ r( i没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

; \/ h% g# W) i" i9 A! m化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 ! X+ M+ q: \. y7 C  A+ g+ O
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。+ {% U. ?' |6 g4 T
ALK一个指标医院要900多 ...

+ |  ^2 F6 _: X: `平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
& ?! l5 a$ s. O, T$ d9 x0 A7 \- p
  h* @# b, Z; O0 @$ ^  E1 H现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表